Back to Search Start Over

Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Authors :
Josep Tabernero
Jose Baselga
Howard Fingert
José-Alejandro Pérez-Fidalgo
Laura Maños
Inma Blasco
Adelaida Piera
Juan Manuel Sanchis-Garcia
JungAh Jung
Jordi Andreu
Susana Roselló
Karthik Venkatakrishnan
Teresa Macarulla
Jeffrey Ecsedy
Desamparados Roda
Elena Elez
Andres Cervantes
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

PDF file, 1635K, Figure S1. MLN8237 dose-escalation and schedule extension schema.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....06cde64f0d7222fa6a3d869e6c18c000